NASDAQ:CRON

Cronos Group Stock Forecast, Price & News

$9.91

-0.74 (-6.95 %)

(As of 01/25/2021 12:00 AM ET)

Add

Compare

Today's Range

$9.81

Now: $9.91▼

$10.62

50-Day Range

$6.94

MA: $8.69▼

$11.26

52-Week Range

$4.00

Now: $9.91▼

$11.75

Volume5.62 million shs

Average Volume7.00 million shs

Market Capitalization$3.53 billion

P/E Ratio41.29

Dividend YieldN/A

Beta2.07

Cronos Group Inc. operates as a cannabinoid company in the United States and internationally. It manufactures, markets, and distributes hemp-derived supplements and cosmetic products through ecommerce, retail, and hospitality partner channels. The company is also involved in the cultivation, manufacture, and marketing of cannabis and cannabis-derived products for the medical and adult-use markets. Its brand portfolio includes PEACE NATURALS, a global wellness platform; adult-use brands comprise COVE and Spinach; and hemp-derived CBD brands consists of Lord Jones and PEACE+. Cronos Group Inc. is based in Toronto, Canada.

MarketRank^™

Overall MarketRank^™

0.66 out of 5 stars

Medical Sector

1237th out of 1,922 stocks

Medicinals & Botanicals Industry

16th out of 33 stocks

1.0 Analyst's Opinion

Consensus Rating
Cronos Group has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on 2 buy ratings, 4 hold ratings, and 2 sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $8.19, Cronos Group has a forecasted downside of 17.4% from its current price of $9.91.
Amount of Analyst Coverage
Cronos Group has only been the subject of 2 research reports in the past 90 days.

2.3 Community Rank

Outperform Votes
Cronos Group has received 440 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Cronos Group has received 512 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Cronos Group has received 53.78% “underperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Cronos Group and other stocks. Vote “Outperform” if you believe CRON will outperform the S&P 500 over the long term. Vote “Underperform” if you believe CRON will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Cronos Group does not currently pay a dividend.
Dividend Growth
Cronos Group does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Cronos Group insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $16,761,991.00 in company stock.
Percentage Held by Insiders
Only 7.93% of the stock of Cronos Group is held by insiders.
Percentage Held by Institutions
Only 11.75% of the stock of Cronos Group is held by institutions.

0.0 Earnings and Valuation

Earnings Growth
Earnings for Cronos Group are expected to decrease in the coming year, from ($0.08) to ($0.24) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Cronos Group is 41.29, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 24.40.
Price to Earnings Ratio vs. Sector
The P/E ratio of Cronos Group is 41.29, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 36.58.
Price to Book Value per Share Ratio
Cronos Group has a P/B Ratio of 1.98. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Medicinals & botanicals

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:CRON

Previous Symbol

CUSIPN/A

CIKN/A

Webwww.thecronosgroup.com

Phone416-504-0004

Employees631

Year FoundedN/A

Debt

Debt-to-Equity RatioN/A

Current Ratio9.75

Quick Ratio9.36

Price-To-Earnings

Trailing P/E Ratio41.29

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$25.64 million

Price / Sales137.51

Cash Flow$0.67 per share

Price / Cash Flow14.76

Book Value$5.01 per share

Price / Book1.98

Profitability

EPS (Most Recent Fiscal Year)$0.67

Net Income$1.17 billion

Net Margins266.31%

Return on Equity-1.61%

Return on Assets-1.41%

Miscellaneous

Outstanding Shares355,773,000

Market Cap$3.53 billion

Next Earnings Date3/29/2021 (Estimated)

OptionableOptionable

$9.91

-0.74 (-6.95 %)

(As of 01/25/2021 12:00 AM ET)

30 days | 90 days | 365 days | Advanced Chart

Receive CRON News and Ratings via Email

Sign-up to receive the latest news and ratings for CRON and its competitors with MarketBeat's FREE daily newsletter.

Cronos Group (NASDAQ:CRON) Frequently Asked Questions

How has Cronos Group's stock been impacted by Coronavirus?

Cronos Group's stock was trading at $5.41 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, CRON stock has increased by 83.2% and is now trading at $9.91.
View which stocks have been most impacted by COVID-19.

Is Cronos Group a buy right now?

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Cronos Group in the last twelve months. There are currently 2 sell ratings, 4 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Cronos Group stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CRON, but not buy additional shares or sell existing shares.
View analyst ratings for Cronos Group or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Cronos Group?

Wall Street analysts have given Cronos Group a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Cronos Group wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Cronos Group's next earnings date?

Cronos Group is scheduled to release its next quarterly earnings announcement on Monday, March 29th 2021.
View our earnings forecast for Cronos Group.

How were Cronos Group's earnings last quarter?

Cronos Group Inc. (NASDAQ:CRON) posted its earnings results on Thursday, November, 5th. The company reported $0.19 EPS for the quarter, beating analysts' consensus estimates of ($0.06) by $0.25. The company had revenue of $11.36 million for the quarter, compared to analysts' expectations of $14.80 million. Cronos Group had a negative trailing twelve-month return on equity of 1.61% and a net margin of 266.31%. Cronos Group's quarterly revenue was up 96.2% on a year-over-year basis. During the same period in the previous year, the company posted $1.62 earnings per share.
View Cronos Group's earnings history.

What price target have analysts set for CRON?

8 brokers have issued 12 month price targets for Cronos Group's shares. Their forecasts range from $5.00 to $11.00. On average, they expect Cronos Group's stock price to reach $8.19 in the next year. This suggests that the stock has a possible downside of 17.4%.
View analysts' price targets for Cronos Group or view Wall Street analyst' top-rated stocks.

Are investors shorting Cronos Group?

Cronos Group saw a decrease in short interest in the month of December. As of December 31st, there was short interest totaling 28,510,000 shares, a decrease of 20.0% from the December 15th total of 35,620,000 shares. Based on an average daily trading volume, of 5,370,000 shares, the days-to-cover ratio is currently 5.3 days. Approximately 15.7% of the shares of the company are short sold.
View Cronos Group's Short Interest.

Who are some of Cronos Group's key competitors?

Some companies that are related to Cronos Group include Canopy Growth (CGC), STADA Arzneimittel Aktiengesellschaft (STDAF), Aphria (APHA), Tilray (TLRY), USANA Health Sciences (USNA), Aurora Cannabis (ACB), HEXO (HEXO), Sundial Growers (SNDL), Canopy Rivers (RIV), ChromaDex (CDXC), Charlie's (CHUC), MediWound (MDWD), Natural Alternatives International (NAII), Glucose Health (GLUC) and Happiness Biotech Group (HAPP).
View all of CRON's competitors.

What other stocks do shareholders of Cronos Group own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cronos Group investors own include (CGC), Aurora Cannabis (ACB), Tilray (TLRY), (APHA), NVIDIA (NVDA), Advanced Micro Devices (AMD), Dollar Tree (DLTR), Micron Technology (MU), Alibaba Group (BABA) and OrganiGram (OGI).

Who are Cronos Group's key executives?

Cronos Group's management team includes the following people:

Mr. Michael Ryan Gorenstein, Exec. Chairman (Age 34, Pay $333.57k)
Mr. Jerry Filomena Barbato, Chief Financial Officer (Age 45, Pay $299.63k)
Ms. Xiuming Shum, Exec. VP of Legal and Regulatory Affairs & Corp. Sec. (Age 35, Pay $190.18k)
Mr. Kurt Thomas Schmidt B.Sc., M.B.A., Pres & CEO (Age 64)
Mr. Shayne J. Laidlaw, Director of Investor Relations & Strategy
Mr. Eric Klein, Head of Marketing
Ms. Shannon Buggy, Sr. VP & Global Head of People
Ms. Anna Shlimak, Sr. VP of Corp. Affairs (Age 35)
Dr. Todd K. Abraham, Chief Innovation Officer (Age 66)
Puneet Mathur, VP & Controller

What is Cronos Group's stock symbol?

Cronos Group trades on the NASDAQ under the ticker symbol "CRON."

Who are Cronos Group's major shareholders?

Cronos Group's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Janney Montgomery Scott LLC (0.04%), Kestra Advisory Services LLC (0.02%), AdvisorShares Investments LLC (0.01%), Traynor Capital Management Inc. (0.01%), Kestra Private Wealth Services LLC (0.01%) and International Assets Investment Management LLC (0.00%). Company insiders that own Cronos Group stock include Jason Marc Adler, Michael Ryan Gorenstein and Todd Kevin Abraham.
View institutional ownership trends for Cronos Group.

Which major investors are buying Cronos Group stock?

CRON stock was bought by a variety of institutional investors in the last quarter, including Traynor Capital Management Inc., Kestra Advisory Services LLC, International Assets Investment Management LLC, AdvisorShares Investments LLC, Kestra Private Wealth Services LLC, Janney Montgomery Scott LLC, and Global Retirement Partners LLC.
View insider buying and selling activity for Cronos Group or or view top insider-buying stocks.

How do I buy shares of Cronos Group?

Shares of CRON can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Cronos Group's stock price today?

One share of CRON stock can currently be purchased for approximately $9.91.

How big of a company is Cronos Group?

Cronos Group has a market capitalization of $3.53 billion and generates $25.64 million in revenue each year. The company earns $1.17 billion in net income (profit) each year or $0.67 on an earnings per share basis. Cronos Group employs 631 workers across the globe.

What is Cronos Group's official website?

The official website for Cronos Group is www.thecronosgroup.com.

How can I contact Cronos Group?

Cronos Group's mailing address is 111 PETER STREET SUITE 300, TORONTO A6, M5V 2G9. The company can be reached via phone at 416-504-0004.

This page was last updated on 1/25/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here